 The European Commission EC has granted marketing authorization to PTC Therapeutics Incs NASDAQ: PTCT Evrysdi risdiplam for the treatment of spinal muscular atrophy SMA in patients two months and older. Evrysdi will be for SMA Type 1, Type 2, or Type 3 patients with one to four SMN2 copies. 